Article | April 15, 2021

Reducing Human Error In Gmp Pharma/Biopharma Operations

Source: CAI

By Harry Benson

Business employee iStock-903585992

In the pharmaceutical and biotech industries, delays in getting products to market cost companies revenue and inhibit patient access to their medications. CAI clients often seek help in closing open investigations, but ignore the source of these investigations, even while product sits quarantined. Where clients really need help is in cutting human error off at the source. Industry average deviation costs generally range from $25,000 to $55,000, yet they can top $1,000,000 per deviation if product loss is involved. Investigating one deviation alone can cost a company thousands of dollars. When considering the cost of heroic efforts to produce and release batches, subsequent employee turnover, and potential downtime, cost increases exponentially.

A Human Performance approach leans on structured methods that assess a site’s processes where human error presents the most risk, then implementing solutions that stop these errors at the source. The resulting solutions may be cultural, procedural, or technical in nature, and could fall within any department or workstream of the business where humans are involved. Eliminating deviations, particularly recurring ones, will allow your site to move product to market more quickly and efficiently.

This blog explores the factors within an organization’s control that impact ongoing human performance.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Cell & Gene? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: